HIV DART: Frontiers in Drug Development for Antiretroviral Therapies

描述（由申请人提供）： 治疗方面的进展已将艾滋病毒从一种致命疾病转变为一种长期慢性疾病，在联合治疗出现之前，艾滋病毒是受感染者的现实。正如预期的那样，需要终身治疗的人数正在增加，仍然需要改进副作用更少的治疗方法，以及有一天可能根除这种病毒的方法。对于传染病医护人员和研究人员来说，跟上新药开发的步伐，以促进新的和有效的艾滋病毒疗法的开发，特别是在第三世界国家，这是至关重要的。HIV DART：抗逆转录病毒治疗药物开发前沿是两年一度的会议，旨在吸引医生，临床医生，护士，科学家和HIV，合并感染（HBV/HCV）和逆转录病毒学领域的临床研究人员。 具体目标：（1）将临床医生、护士、研究人员和基础科学家聚集在一起，增进对抗逆转录病毒研究中正在进行的药物开发过程的了解;（2）将生物学、化学、药理学和临床研究领域结合起来，使科学界进一步了解艾滋病毒感染治疗目前和未来的挑战; 3）通过参加者奖学金，补充和加强对各国代表性不足的科学家、年轻研究生、护士和/或博士后研究员的培训。 教育目标：1）了解病毒靶点在药物发现和开发过程中的作用; 2）确定逆转录病毒的新治疗药物和病毒靶点; 3）开发改进的策略以减少或消除耐药性和毒性; 4）了解宿主和病毒持久性以根除艾滋病毒; 5）开发杀微生物剂和其他预防方法; 6）了解肝炎合并感染对艾滋病毒感染者管理的后果; 7）提供与临床药物开发兼容的新型免疫学方法的见解; 8）开发有针对性的方法来改善抗逆转录病毒药物的药理学;和9）了解儿科和老龄化人群中的艾滋病毒治疗。 设计与方法： HIV DART计划将由国际公认的计划委员会设计，并在有利于地球仪参加的地点进行为期3.5天的活动。它将包括口头和海报形式的科学介绍。继续医学教育认证理事会（ACCME）认证计划将为代表和教师之间的正式和非正式互动提供充足的时间。艾滋病毒DART通常发生在美国和美洲。相关性：HIV DART：Frontiers in Drug Development for Antiretroviral Therapies是一个两年一次的国际会议，为来自地球仪（包括第三世界国家）的传染病医疗工作者和研究人员提供了一个论坛，以了解新的和有效的艾滋病毒疗法的新发展。艾滋病毒灾难援助反应队还鼓励年轻科学家参与，向那些有接受的演讲提供奖学金。HIV DART为医生提供经认证的继续医学教育培训，确保对全世界的艾滋病毒治疗产生持久和积极的公共卫生影响。

DESCRIPTION (provided by applicant): Advances in treatment have transformed HIV from being a fatal disease, which was the reality for infected individuals before the advent of combination treatment, into a long-term chronic condition. As expected, the number of individuals requiring life-long therapy is increasing and the need for improved therapies with fewer side effects are still needed, as well as approaches that may one day eradicate this virus. It is critical for infectious disease healthcare workers and researchers to keep abreast of new drug developments to facilitate the development of novel and potent therapies for HIV, especially in third world countries. HIV DART: Frontiers in Drug Development for Antiretroviral Therapy is a biennial conference to interest physicians, clinicians, nurses, scientists and clinical researchers in the HIV, co-infection (with HBV/HCV), and retrovirology arenas. Specific Aims: 1) Assemble clinicians, nurses, researchers and basic scientists together to advance knowledge of the ongoing drug development processes in antiretroviral research; 2) Blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection; and 3) Supplement and enhance the training of underrepresented scientists from various countries, young graduate students, nurses, and/or post-doctoral fellows through attendee scholarships. Educational Objectives: 1) Understand the role of viral targets in the drug discovery and development process; 2) Identify novel therapeutic agents and viral targets for retroviruses; 3) Develop improved strategies to reduce or eliminate drug-resistance and toxicity; 4) Understand reservoirs and viral persistence towards HIV eradication; 5) Develop microbicides and other preventative approaches; 6) Understand the consequences of hepatitis co-infection on the management of HIV-infected individuals; 7) Provide insights on novel immunological approaches compatible with clinical drug development; 8) Develop targeted approaches to improve the pharmacology of antiretroviral agents; and 9) Understand HIV therapy in pediatrics and the aging population. Design & Methods: The HIV DART program will be designed by an internationally-recognized Program Committee, and conducted over 3.5 days in locations conducive to attendance from around the globe. It will include scientific presentations in both oral and poster presentation formats. The Accreditation Council for Continuing Medical Education (ACCME) accredited program will provide ample time for formal and informal interactions between delegates and faculty. HIV DART usually takes place in the United States and the Americas. Relevance: HIV DART: Frontiers in Drug Development for Antiretroviral Therapies is an international biennial conference that provides a forum for infectious disease healthcare workers and researchers from around the globe, including third world countries, to learn about new developments in novel and potent therapies for HIV. HIV DART also encourages young scientists to participate by providing scholarships to those that have an accepted presentation. HIV DART provides accredited Continuing Medical Education training for physicians, ensuring a lasting and positive public health impact on treatment of HIV throughout the world.